Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach
American Journal of Physiology-Endocrinology and Metabolism, 2000•journals.physiology.org
The traditional methods for the assessment of insulin sensitivity yield only a single index, not
the whole dose-response curve information. This curve is typically characterized by a
maximally insulin-stimulated glucose clearance (Clmax) and an insulin concentration at half-
maximal response (EC50). We developed an approach for estimating the whole dose-
response curve with a single in vivo test, based on the use of tracer glucose and exogenous
insulin administration (two steps of 20 and 200 mU⋅ min− 1⋅ m− 2, 100 min each). The …
the whole dose-response curve information. This curve is typically characterized by a
maximally insulin-stimulated glucose clearance (Clmax) and an insulin concentration at half-
maximal response (EC50). We developed an approach for estimating the whole dose-
response curve with a single in vivo test, based on the use of tracer glucose and exogenous
insulin administration (two steps of 20 and 200 mU⋅ min− 1⋅ m− 2, 100 min each). The …
The traditional methods for the assessment of insulin sensitivity yield only a single index, not the whole dose-response curve information. This curve is typically characterized by a maximally insulin-stimulated glucose clearance (Clmax) and an insulin concentration at half-maximal response (EC50). We developed an approach for estimating the whole dose-response curve with a single in vivo test, based on the use of tracer glucose and exogenous insulin administration (two steps of 20 and 200 mU ⋅ min− 1 ⋅ m− 2, 100 min each). The effect of insulin on plasma glucose clearance was calculated from non-steady-state data by use of a circulatory model of glucose kinetics and a model of insulin action in which glucose clearance is represented as a Michaelis-Menten function of insulin concentration with a delay (t 1/2). In seven nondiabetic subjects, the model predicted adequately the tracer concentration: the model residuals were unbiased, and their coefficient of variation was similar to the expected measurement error (∼3%), indicating that the model did not introduce significant systematic errors. Lean (n= 4) and obese (n = 3) subjects had similar half-times for insulin action (t 1/2 = 25 ± 9 vs. 25 ± 8 min) and maximal responses (Clmax = 705 ± 46 vs. 668 ± 259 ml ⋅ min− 1 ⋅ m− 2, respectively), whereas EC50 was 240 ± 84 μU/ml in the lean vs. 364 ± 229 μU/ml in the obese (P < 0.04). EC50 and the insulin sensitivity index (ISI, initial slope of the dose-response curve), but not Clmax, were related to body adiposity and fat distribution with r of 0.6–0.8 (P < 0.05). Thus, despite the small number of study subjects, we were able to reproduce information consistent with the literature. In addition, among the lean individuals, t 1/2 was positively related to the ISI (r = 0.72, P < 0.02). We conclude that the test here presented, based on a more elaborate representation of glucose kinetics and insulin action, allows a reliable quantitation of the insulin dose-response curve for whole body glucose utilization in a single session of relatively short duration.
American Physiological Society